Q32 Bio Inc. (QTTB)
NASDAQ: QTTB · Real-Time Price · USD
1.660
+0.110 (7.10%)
At close: May 12, 2025, 4:00 PM
1.610
-0.050 (-2.99%)
After-hours: May 12, 2025, 4:10 PM EDT
Q32 Bio Employees
As of December 31, 2024, Q32 Bio had 43 total employees, including 42 full-time and 1 part-time employees. The number of employees increased by 6 or 16.22% compared to the previous year.
Employees
43
Change (1Y)
6
Growth (1Y)
16.22%
Revenue / Employee
n/a
Profits / Employee
-$1,390,535
Market Cap
20.25M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 43 | 6 | 16.22% |
Dec 31, 2023 | 37 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
QTTB News
- 4 days ago - Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 12 days ago - Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata - PRNewsWire
- 26 days ago - Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata - PRNewsWire
- 2 months ago - Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 2 months ago - Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting - PRNewsWire
- 2 months ago - Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting - PRNewsWire
- 2 months ago - Q32 Bio to Participate in Upcoming March Investor Conferences - PRNewsWire
- 3 months ago - Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata - PRNewsWire